VANDRIA

LIVE

Serial Number

90905974

Owner

Amazentis SA

Attorney

Joshua S. Jarvis, Esq.

Filing Date

Aug 27, 2021

Add to watchlist:

No watchlists yet

+ Create New Watchlist

View on USPTO

VANDRIA Trademark

Serial Number: 90905974 • Registration: 8026795

VANDRIA is a trademark filed by Amazentis SA on August 27, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Trademark Classes

Class 5 - Pharmaceuticals

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Owner Contact Info

Amazentis SA (43 trademarks)

Parc Scientifique EPFL, PSE-C
Ecublens 1024 , CH

Entity Type: 03

VANDRIA SA

LAUSANNE 1015 , CH

Entity Type: 03

Legal Representation

Attorney of Record

Joshua S. Jarvis, Esq.

650 trademarks filed View all →

Correspondence Address

Joshua S. Jarvis, Esq. FOLEY HOAG LLP

155 SEAPORT BOULEVARD

SEAPORT WEST

BOSTON, MA 02210-2600

United States

Trademark Details

Filing Date

August 27, 2021

Registration Date

November 18, 2025

Published for Opposition

October 18, 2022

Goods & Services

Research and development of pharmaceuticals in the fields of mitochondrial diseases, disorders, and conditions, cardiovascular diseases, disorders, and conditions, musculoskeletal diseases, disorders, and conditions, muscular diseases, disorders, and conditions, bone diseases, disorders, and conditions, neurological and neurodegenerative diseases, disorders, and conditions, metabolic diseases, disorders, and conditions, renal diseases, disorders, and conditions, ophthalmological diseases, disorders, and conditions, oncological diseases, disorders, and conditions, immune system and autoimmune diseases, disorders, and conditions, endocrine system diseases, disorders, and conditions, pulmonary and respiratory diseases, disorders, and conditions, hepatic diseases, disorders, and conditions, gastrointestinal diseases, disorders, and conditions, and diseases, disorders, and conditions related to aging

Pharmaceuticals for the treatment of mitochondrial diseases, disorders, and conditions, cardiovascular diseases, disorders, and conditions, musculoskeletal diseases, disorders, and conditions, muscular diseases, disorders, and conditions, bone diseases, disorders, and conditions, neurological and neurodegenerative diseases, disorders, and conditions, metabolic diseases, disorders, and conditions, renal diseases, disorders, and conditions, ophthalmological diseases, disorders, and conditions, oncological diseases, disorders, and conditions, immune system and autoimmune diseases, disorders, and conditions, endocrine system diseases, disorders, and conditions, pulmonary and respiratory diseases, disorders, and conditions, hepatic diseases, disorders, and conditions, gastrointestinal diseases, disorders, and conditions, and diseases, disorders, and conditions related to aging

Filing History

POST PUBLICATION AMENDMENT REVIEWED – NO ACTION TAKEN

Dec 19, 2025 PPAD

ASSIGNED TO PETITION STAFF

Dec 11, 2025 APET

NOTICE OF REGISTRATION CONFIRMATION EMAILED

Nov 18, 2025 NRCC

REGISTERED-PRINCIPAL REGISTER

Nov 18, 2025 R.PR

1(B) BASIS DELETED; PROCEED TO REGISTRATION

Oct 24, 2025 DP1B

TEAS POST PUBLICATION AMENDMENT RECEIVED

Oct 23, 2025 EPPA

NOTICE OF ALLOWANCE CANCELLED

Oct 23, 2025 IUCN

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Aug 26, 2025 EXRA

SOU EXTENSION 5 GRANTED

Aug 26, 2025 EX5G

CASE ASSIGNED TO INTENT TO USE PARALEGAL

Aug 26, 2025 AITU

SOU TEAS EXTENSION RECEIVED

Apr 23, 2025 EEXT

SOU EXTENSION 5 FILED

Apr 22, 2025 EXT5

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Oct 25, 2024 EXRA

SOU EXTENSION 4 GRANTED

Oct 25, 2024 EX4G

SOU EXTENSION 4 FILED

Oct 25, 2024 EXT4

SOU TEAS EXTENSION RECEIVED

Oct 25, 2024 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Apr 9, 2024 EXRA

SOU EXTENSION 3 GRANTED

Apr 8, 2024 EX3G

SOU EXTENSION 3 FILED

Apr 8, 2024 EXT3

SOU TEAS EXTENSION RECEIVED

Apr 8, 2024 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Sep 20, 2023 EXRA

SOU EXTENSION 2 GRANTED

Sep 18, 2023 EX2G

SOU EXTENSION 2 FILED

Sep 18, 2023 EXT2

SOU TEAS EXTENSION RECEIVED

Sep 18, 2023 EEXT

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Mar 25, 2023 EXRA

SOU EXTENSION 1 GRANTED

Mar 23, 2023 EX1G

SOU EXTENSION 1 FILED

Mar 23, 2023 EXT1

SOU TEAS EXTENSION RECEIVED

Mar 23, 2023 EEXT

NOA E-MAILED - SOU REQUIRED FROM APPLICANT

Dec 13, 2022 NOAM

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

Oct 18, 2022 NPUB

PUBLISHED FOR OPPOSITION

Oct 18, 2022 PUBO

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

Sep 28, 2022 NONP

APPROVED FOR PUB - PRINCIPAL REGISTER

Sep 9, 2022 CNSA

TEAS/EMAIL CORRESPONDENCE ENTERED

Sep 2, 2022 TEME

CORRESPONDENCE RECEIVED IN LAW OFFICE

Sep 2, 2022 CRFA

ASSIGNED TO LIE

Sep 1, 2022 ALIE

TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED

Aug 3, 2022 ERSI

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

Jun 6, 2022 GNS3

LETTER OF SUSPENSION E-MAILED

Jun 6, 2022 GNSL

SUSPENSION LETTER WRITTEN

Jun 6, 2022 CNSL

ASSIGNED TO EXAMINER

Jun 2, 2022 DOCK

AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP

Jan 26, 2022 ASGN

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Sep 29, 2021 NWOS

NEW APPLICATION ENTERED

Aug 31, 2021 NWAP

Related Trademarks

More from this Owner

MITOPURE

IT’S ABOUT TIME.

TIMELINE

More in Same Class

SINUGEL TOPICAL SINUS THERAPEUTICS